B
Braidwell Portfolio holdings
AUM
$2.7B
Turnover
43.12%
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+4.4%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.06B
AUM Growth
+$28.4M
(+0.94%)
Cap. Flow
-$1.31B
Cap. Flow
% of AUM
-42.81%
Top 10 Holdings %
Top 10 Hldgs %
37.02%
Holding
95
New
15
Increased
19
Reduced
16
Closed
14
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keros Therapeutics
KROS
|
+$50.1M |
| 2 |
Boston Scientific
BSX
|
+$37.5M |
| 3 |
Viridian Therapeutics
VRDN
|
+$30.9M |
| 4 |
Maravai LifeSciences
MRVI
|
+$24.4M |
| 5 |
Axonics, Inc. Common Stock
AXNX
|
+$21.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$90.4M |
| 2 |
Glaukos
GKOS
|
+$43.8M |
| 3 |
Amgen
AMGN
|
+$39M |
| 4 |
Intuitive Surgical
ISRG
|
+$30M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$29.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.2% |
| 2 | Miscellaneous | 45.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Mineralys Therapeutics
MLYS
$1.86B
| $9.38M | 0.31% |
550,300
| – | – |
2023 Q1
1 quarter
|
|
|
MRTX
52
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.69M | 0.28% |
240,625
-211,375
| -47% | -$8.71M |
2022 Q4
2 quarters
|
|
|
SGEN
53
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.18M | 0.27% |
+42,497
| New | +$8.44M |
2023 Q2
0 quarters
|
|
54
Agenus
AGEN
$302M
| $7.52M | 0.25% |
+234,897
| New | +$7.52M |
2023 Q2
0 quarters
|
|
55
Nuvation Bio
NUVB
$1.66B
| $7.42M | 0.24% |
4,122,900
| – | – |
2022 Q4
2 quarters
|
|
56
Adaptive Biotechnologies
ADPT
$4.06B
| $4.35M | 0.14% |
648,451
| – | – |
2023 Q1
1 quarter
|
|
57
DELISTED
Esperion Therapeutics
ESPR
| $1.25M | 0.04% |
895,949
-315,570
| -26% | -$441K |
2022 Q4
2 quarters
|
|
58
Alphatec Holdings
ATEC
$1.6B
| $457K | 0.01% |
+25,431
| New | +$396K |
2023 Q2
0 quarters
|
|
59
DELISTED
Arcellx
ACLX
| – | – |
-333,800
| Closed | -$10.3M | – |
|
|
60
Amgen
AMGN
$230B
| – | – |
-161,500
| Closed | -$39M | – |
|
61
argenx
ARGX
$52B
| – | – |
-24,600
| Closed | -$9.17M | – |
|
62
Avalo Therapeutics
AVTX
$632M
| – | – |
-1,030
| Closed | -$433K | – |
|
63
Globus Medical
GMED
$10.2B
| – | – |
-335,200
| Closed | -$19M | – |
|
64
Immatics
IMTX
$1.04B
| – | – |
-322,287
| Closed | -$2.22M | – |
|
65
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-134,232
| Closed | -$13.8M | – |
|
66
Pacific Biosciences
PACB
$615M
| – | – |
-1,097,300
| Closed | -$12.7M | – |
|
67
Syndax Pharmaceuticals
SNDX
$1.21B
| – | – |
-920,049
| Closed | -$19.4M | – |
|
68
Steris
STE
$21.1B
| – | – |
-95,694
| Closed | -$18.3M | – |
|
69
Transmedics
TMDX
$2.61B
| – | – |
-98,459
| Closed | -$7.46M | – |
|
70
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| – | – |
-63,331
| Closed | -$2.48M | – |
|
|
ISEE
71
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-3,714,672
| Closed | -$90.4M | – |
|
|
BLU
72
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-4,126,194
| Closed | -$29.7M | – |
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q2 2023 Portfolio in Review
As of Q2 2023, Braidwell held 95 positions worth $3.06B, up 0.94% from $3.03B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Braidwell withdrew a net $1.31B in Q2 2023, closing 14 positions and reducing 16 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $90.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 54% a quarter earlier, followed by Miscellaneous.
Against the trend, Braidwell opened a new position in Keros Therapeutics worth $46M.
- Braidwell's largest Q2 2023 buy was Keros Therapeutics: 1,143,865 shares worth $46M.
- Braidwell added most to Axonics, Inc. Common Stock in Q2 2023, an estimated $21.7M increase.
- Braidwell's biggest Q2 2023 reduction was Glaukos, cutting an estimated $43.8M.
- Braidwell fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $90.4M.
- Braidwell's ten largest holdings make up 37% of its $3.06B portfolio in Q2 2023.
- Braidwell opened 15 new positions and closed 14 in Q2 2023.
- Braidwell's portfolio value rose 0.94% quarter-over-quarter to $3.06B.
Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.